Luigi Terracciano

ORCID: 0000-0002-9393-9660
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Liver Disease Diagnosis and Treatment
  • Genetic factors in colorectal cancer
  • Cancer Genomics and Diagnostics
  • RNA modifications and cancer
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Immune cells in cancer
  • Food Allergy and Anaphylaxis Research
  • Cancer, Hypoxia, and Metabolism
  • Immune Cell Function and Interaction
  • Colorectal Cancer Treatments and Studies
  • Liver Diseases and Immunity
  • Immunotherapy and Immune Responses
  • Pancreatic and Hepatic Oncology Research
  • Ferroptosis and cancer prognosis
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Allergic Rhinitis and Sensitization
  • Cancer Cells and Metastasis
  • Colorectal Cancer Surgical Treatments
  • Liver physiology and pathology
  • Hepatitis C virus research
  • Cancer-related molecular mechanisms research
  • Asthma and respiratory diseases
  • Monoclonal and Polyclonal Antibodies Research
  • Radiopharmaceutical Chemistry and Applications

Humanitas University
2009-2025

IRCCS Humanitas Research Hospital
2021-2025

University of Pavia
1989-2024

Istituti di Ricovero e Cura a Carattere Scientifico
2009-2024

Showa University Northern Yokohama Hospital
2024

Policlinico San Matteo Fondazione
2024

Italian Society of Physiotherapy
2024

University Hospital of Basel
2014-2023

Fondazione IRCCS Istituto Nazionale dei Tumori
2023

Weatherford College
2023

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide. The current standard therapy for hepatitis (CHC) consists combination pegylated IFN alpha (pegIFNα) and ribavirin. It achieves sustained viral clearance in only 50–60% patients. To learn more about molecular mechanisms underlying treatment failure, we investigated IFN-induced signaling paired biopsies collected from CHC patients before after administration pegIFNα. In with rapid virological response to...

10.1073/pnas.0707882105 article EN Proceedings of the National Academy of Sciences 2008-05-09

This article was originally published online on 23 April 2010 Alessandro Fiocchi, MD, Pediatric Division, Department of Child and Maternal Medicine, University Milan Medical School at the Melloni Hospital, 20129, Italy. Holger Schünemann, MD,a Clinical Epidemiology & Biostatistics, McMaster Health Sciences Centre, 1200 Main Street West Hamilton, ON L8N 3Z5, Canada. Sami L. Bahna, Pediatrics Allergy Immunology, Louisiana State Center, Shreveport, LA 71130. Andrea Von Berg, Research Institute,...

10.1097/wox.0b013e3181defeb9 article EN cc-by-nc-nd World Allergy Organization Journal 2010-01-01

Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether PD-1/PD-L1 differently expressed oncogene-addicted NSCLC. We analysed a cohort of 125 NSCLC patients, including 56 EGFR mutated, 29 KRAS 10 ALK translocated 30 EGFR/KRAS/ALK wild type. PD-L1 PD-1 expression were assessed by immunohistochemistry. All cases with moderate or strong staining (2+/3+) >5% tumour cells considered as...

10.1038/bjc.2014.555 article EN cc-by-nc-sa British Journal of Cancer 2014-10-28

To investigate the prognostic role of genomic gain for MET and epidermal growth factor receptor (EGFR) genes in surgically resected non-small-cell lung cancer (NSCLC).This retrospective study included 447 NSCLC patients with available tumor tissue from primary survival data. EGFR status was evaluated by fluorescent situ hybridization (FISH) microarray sections.EGFR FISH results were obtained 376 cases. gene amplification high polysomy (EGFR FISH+) observed 10.4% 32.4% cases, respectively....

10.1200/jco.2008.19.1635 article EN Journal of Clinical Oncology 2009-03-03

Background Prevalence of allergic diseases in infants, whose parents and siblings do not have allergy, is approximately 10% reaches 20–30% those with an first-degree relative. Intestinal microbiota may modulate immunologic inflammatory systemic responses and, thus, influence development sensitization allergy. Probiotics been reported to immune their supplementation has proposed as a preventive intervention.Objective The World Allergy Organization (WAO) convened guideline panel develop...

10.1186/s40413-015-0055-2 article EN cc-by-nc-nd World Allergy Organization Journal 2015-01-01

Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related death. Despite advances in diagnosis and management HCC, biology this tumor remains poorly understood. Recent evidence highlighted long noncoding RNAs (lncRNAs) as crucial determinants HCC development. In study we report lncRNA HOXA transcript at distal tip (HOTTIP) significantly up-regulated specimens. The HOTTIP gene located physical contiguity with HOXA13 directly controls locus expression by way interaction...

10.1002/hep.26740 article EN Hepatology 2013-10-11

Abstract Purpose: Oncogenic gene fusions involving the 3′ region of ROS1 kinase have been identified in various human cancers. In this study, we sought to characterize fusion genes non–small cell lung cancer (NSCLC) and establish proteins as drug targets. Experimental Design: An NSCLC tissue microarray (TMA) panel containing 447 samples was screened for rearrangement by FISH. This assay also used screen patients with NSCLC. positive samples, identity partner determined through inverse PCR...

10.1158/1078-0432.ccr-12-0550 article EN Clinical Cancer Research 2012-08-24

Abstract Hepatocellular nodules in cirrhosis include regenerative (large regenerative, LRN) and dysplastic (low high grade, LGDN HGDN) nodules, early grade 1 HCC (eHCC-G1), overt HCC. The differential diagnosis may be particularly difficult when lesions such as HGDN eHCC-G1 are involved. We investigated the diagnostic yield of a panel 3 putative markers hepatocellular malignancy HSP70, glypican (GPC3), glutamine synthetase (GS). selected 52 surgically removed nonmalignant (15 LRNs, 15 LGDNs,...

10.1002/hep.21531 article EN Hepatology 2007-02-26

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and second frequent cause of cancer-related mortality worldwide. The multikinase inhibitor sorafenib only treatment option for advanced HCC. Due to tumor heterogeneity, its efficacy greatly varies between patients limited due adverse effects drug resistance. Current in vitro models fail recapitulate key features HCCs. We report generation long-term organoid cultures from needle biopsies HCC with various etiologies stages....

10.1016/j.celrep.2018.07.001 article EN cc-by-nc-nd Cell Reports 2018-07-01

Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic approaches, but little data are available about Ep-CAM expression in major human malignancies with respect to level, frequency, tumour stage, grade, histologic type and impact on survival. We analysed immunohistochemical staining tissue microarrays 4046 primary carcinoma samples from colon, stomach, prostate lung cancers for both frequency intensity of under highly standardised conditions. A total...

10.1038/sj.bjc.6602924 article EN cc-by-nc-sa British Journal of Cancer 2006-01-01

Regulatory T cells (T(reg)) inhibit the generation of host-versus-tumor immunity via suppression tumor-specific effector T-cell responses and development immune tolerance to neoplastic cells. The transcription factor forkhead box P3 (FOXP3) is an intracellular key molecule for T(reg) function considered represent most specific cell marker. aim this study was analyze frequency prognostic impact tumor-infiltrating FOXP3(+) in colorectal cancer (CRC) stratified by mismatch-repair (MMR) status....

10.1002/ijc.24989 article EN International Journal of Cancer 2009-10-23

The aim of this study was to elucidate the prognostic impact putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and aldehyde dehydrogenase-1 (ALDH1) in colorectal cancer.A tissue microarray 1420 primary cancers 57 normal mucosa samples immunostained for ALDH1 addition 101 corresponding whole sections. Invasive potential three lines tested.Differences between were observed all (P<0.001). Loss membranous CD166 CD44s linked higher pT (P=0.002, P=0.014), pN (P=0.004, P=0.002), an...

10.1038/sj.bjc.6605762 article EN cc-by-nc-sa British Journal of Cancer 2010-07-01
Coming Soon ...